Industry & Business

Science Foundation Ireland and Pfizer announce exciting new R&D programme for Ireland

 Breaking News
  • Neueda Technologies Establishing a Software Engineering Hub in Athlone Neueda Technologies, a privately-owned IT Training, development and consulting services company headquartered in Belfast, is establishing a Software Engineering Hub in Athlone, Co. Westmeath, employing 200 staff over four years. The project is supported by the Irish Government through IDA Ireland. The company will undertake software development services for global telecommunications and financial services clients at [...]...
  • Progress at Last! – British Irish Chamber Welcomes UK White Paper on Brexit The British Irish Chamber of Commerce has welcomed the publication of the white paper on Brexit by the UK Government but has called for a full agreement on services to be sought.   Commenting after the publication of the white paper, John McGrane, the Director-General of the British Irish Chamber of Commerce, said: “At last we [...]...
  • Fexco to Create 175 New Jobs in Ireland’s South West Irish-international fintech company, Fexco has announced a significant expansion of its operations headquartered in Killorglin, Co Kerry creating 175 new jobs over 3 years. The jobs form part of Fexco’s expansion strategy reinforcing the South West’s position as the driving force of Ireland’s fintech industry. The announcement was made in Killorglin by Julie Sinnamon, CEO of [...]...
  • Reliance on UK Exports Could Lead to High Brexit Cost Increases For Irish Firms Irish-owned firms rely heavily on the UK as the source of intermediate inputs, which are goods used to produce a final product. Over half of the total imports used by Irish-owned firms are sourced in the UK with many importing solely from the UK market. Many Irish-owned companies are therefore highly exposed to cost increases [...]...
  • Center Parcs Serves Up €5.2 Million in Contracts to Irish Food Companies Four of Ireland’s top food companies will benefit from a significant boost to their businesses as Center Parcs announces the awarding of food supplier contracts to its Center Parcs Longford Forest resort – due to open in summer 2019 – worth a combined total of €5.2 million. Center Parcs has awarded the following food supplier contracts: Dublin [...]...

Science Foundation Ireland and Pfizer announce exciting new R&D programme for Ireland

April 14
08:55 2016

sfi-logoScience Foundation Ireland and Pfizer today announced the recipients of the 2016 SFI-Pfizer Biotherapeutics Innovation Award programme. The collaboration between Science Foundation Ireland and Pfizer provides qualified academic researchers with an opportunity to deliver important potential discoveries in the areas of immunology, oncology, cardiovascular and rare diseases.

Supported by the Department of Jobs, Enterprise and Innovation, the SFI-Pfizer Biotherapeutics Innovation Award programme has awarded funding to researchers from across three academic institutions in Ireland including the Royal College Surgeons (RCSI), University College Cork (UCC) and University College Dublin (UCD).

In addition to the funding, academic researchers will have the unique opportunity to work with the Pfizer Global Biotherapeutics Technology (GBT) group, at Grangecastle in Dublin, as well as Pfizer’s R&D innovation engine, the Centers for Therapeutic Innovation. The teams’ research will focus on the application of cutting edge technologies for next generation protein therapies.

Speaking at the announcement, Mr Damien English, TD, Minister for Research, Skills and Innovation, said: “The collaboration between Science Foundation Ireland and Pfizer is an excellent example of how government, industry and academia can work together and share knowledge that could lead to the development of new medical breakthroughs not only for Irish patients but for patients worldwide. The Government continues to encourage and welcome programmes that offer opportunities in research and development in Ireland. Innovative partnerships and meaningful collaboration between industry and academia like this also help to build Ireland’s reputation internationally as a location for excellent scientific research.”

Commenting at the announcement, Prof Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Adviser to the Government of Ireland said, “We are delighted to continue this successful partnership with Pfizer to support innovative research and development that could help deliver significant advances in critical areas of medical need.  The success of the award programme is a reflection of the quality and relevance of academic scientific research in Ireland – excellence and impact.”

Commenting on the announcement, Dr. Paul Duffy, Vice President, Biopharmaceutical Operations and External Supply, Pfizer said, “Pfizer are delighted with the continued collaboration with Science Foundation Ireland. As an organisation we are focused on delivering innovative therapies that significantly improve patients’ lives and investment in early stage research is critical to achieving this. Collaborations between industry and academia remain key in helping to expedite the translation of scientific discoveries into breakthrough therapies that matter for patients in need.”

In 2015, five proposals representing four institutions across Ireland were awarded similar funding. Over the past year the researchers have worked in collaboration with Pfizer colleagues on potential new therapies for diseases including haemophilia, fibrosis, Motor Neuron Disease, psoriasis and Crohn’s disease. A number of these programmes are advancing and are on track to reaching their goals.

The recipients of the SFI-Pfizer Biotherapeutics Innovation Award are:

  • Prof Martin Steinhoff, University College Dublin – Prof Steinhoff leads a translational research team attempting to understand the molecular mechanisms underlying skin inflammation and associated chronic itch, for which there remains a significant unmet clinical need. The team hopes to generate targeting molecules that block the activation of key players in these inflammatory pathways.
  • Dr Anne Moore, University College Cork – The remit of Dr Moore’s group is to develop and translate innovative therapies that modulate immune function. Mounting evidence from recent clinical studies demonstrates that harnessing the body’s own immune response to kill tumour cells can be a very effective mechanism to treat cancer. This collaboration aims to develop a novel strategy that enhances the body’s natural anti-tumour response.
  • Dr Leonie Young and Prof Arnold Hill, Royal College of Surgeons of Ireland – Dr Young and Prof Arnold Hill are interested in the underlying mechanisms that control breast cancer resistance to traditional chemotherapeutics. Their aim is to use pre-clinical models, clinical datasets and breast cancer patient samples to better characterize, and effectively target, treatment resistant breast cancers.

About Author

admin

admin

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4